Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 11
Submit an article Journal homepage
1,702
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations

Rei GotoGraduate School of Business Administration, Keio University, Kanagawa, Japan; Correspondence[email protected]
,
Akihito UdaJapan Medical Affairs, Takeda Pharmaceutical Company Limited, Tokyo, Japan;
,
Shinzo HiroiJapan Medical Affairs, Takeda Pharmaceutical Company Limited, Tokyo, Japan;
,
Kosuke IwasakiMilliman, Tokyo, Japan;
,
Kenta TakashimaMilliman, Tokyo, Japan;
&
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan
Pages 1155-1162 | Received 30 Mar 2017, Accepted 15 Jul 2017, Published online: 16 Aug 2017

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Philip Cornford, Caolan Halpin, Jelena Sassmann, Ian Frankcom & Saran Braybrook. (2023) Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England. Journal of Medical Economics 26:1, pages 208-218.
Read now
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Rei Goto, Akihito Uda, Shinzo Hiroi, Kosuke Iwasaki, Kenta Takashima & Junichi Kurebayashi. (2017) Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. Journal of Medical Economics 20:11, pages 1163-1169.
Read now

Articles from other publishers (1)

Carla S. M. de Freitas & Aleida N. Soares. (2020) Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer. International braz j urol 46:3, pages 383-389.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.